Published Date: 23 Apr 2023
Despite Improvement Efforts, the "State of the Air" Report Highlights Issues.
Read Full Newsargenx's efgartigimod-alfa therapy was approved for seropositive generalized myasthenia gravis in 2021.
Early initiation of opicapone significantly reduces OFF time and enhances ON time in patients with recently diagnosed Parkinson's disease, improving overall treatment outcomes.
The FDA requested the full data from the phase 3 HOPE-3 study as part of its review of the biologics license application for deramiocel, which Capricor plans to submit in February 2026.
A five-year analysis from the National RLS Opioid Registry found that most patients with dopamine agonist augmented restless legs syndrome maintained stable, low-dose opioid therapy with sustained symptom control.
Personalized Care Improvements Identified for Older Patients with Skin Cancer
New Findings on Acne Incidence in Transgender Individuals, With Howa Yeung, MD, MSc
What to Expect at the 2026 Maui Derm Conference
1.
Veterans of the Navy have high lung cancer rates associated with asbestos use.
2.
What is a "cancer vaccine" and is it the same as a COVID vaccine?
3.
According to research, the mineralization of the bone matrix controls the growth of tumor cells.
4.
La interacción GBP3-STING en el glioblastoma coordina la respuesta deficiente al temozolomide.
5.
Cancer patients with HIV have demonstrated safety with immune checkpoint inhibitors.
1.
Harnessing Cuproptosis: A Novel Nanomedicine Strategy for Triple-Negative Breast Cancer
2.
Managing High Potassium Levels: A Comprehensive Guide to Veltassa
3.
Exploring the Benefits of Endari: How This Natural Remedy Can Help You Live a Healthier Life
4.
Exploring New Treatment Strategies for Mantle Cell Lymphoma
5.
Exploring Dyscrasias: Uncovering the Causes and Treatments of Unusual Blood Disorders
1.
International Lung Cancer Congress®
2.
Genito-Urinary Oncology Summit 2026
3.
Future NRG Oncology Meeting
4.
ISMB 2026 (Intelligent Systems for Molecular Biology)
5.
Annual International Congress on the Future of Breast Cancer East
1.
A Conclusive Discussion on CROWN Trial and the Dawn of a New Era in Frontline Management of ALK+ NSCLC
2.
An Eagles View - Evidence-based discussion on Iron Deficiency Anemia- Further Talks
3.
An In-Depth Look At The Signs And Symptoms Of Lymphoma
4.
Understanding the Multifaceted Advantages of CDK4/6 Inhibitors in HR+/HER2- PALOMA 2 Study.
5.
Guideline Recommendations of Lorlatinib as First-Line Treatment for ALK+ NSCLC
© Copyright 2025 Hidoc Dr. Inc.
Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation